CClinicalTrials.gg
CompletedNCT02937090Updated Nov 6, 2017

Intestinal Microbiota Survey of Polycystic Ovary Syndrome

An observational study in Polycystic Ovary Syndrome, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Completed at 1 site in China. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Polycystic Ovary Syndrome is kind of disease with unclear etiology. Recent studies on intestinal microbiota have raised the possibility that dysbiosis of intestinal microbiota maybe a novel theory for the development of Polycystic Ovary Syndrome. Hence, the investigators will compare the intestinal microbiota composition and diversity in PCOS with age, BMI-matched control and then assess whether intestinal microbiota modification is associated with clinical and biological parameters.

Read the detailed description

The goal of this study is to investigate and compare the composition of the intestinal microbiota in patients with PCOS and age, BMI-matched control. In addition, the investigators will investigate the relationship between alterations in the intestinal microbiota, clinical phenotype, biochemical analysis, body composition, inflammation and food consumption habit. The investigators hypothesize that alterations in the intestinal microbiota are associated with increased immune activation and progression of PCOS. Based on this hypothesis, the investigators propose the following aims:

Aim 1. Identify and enroll cohort with PCOS and age, BMI-matched control to study the role of intestinal microbiota on the development of PCOS.

  1. Enroll participants at Drum Tower Hospital. Identify and classify participants through initial clinical evaluation, collect clinical metadata, obtain and process blood and stool samples for analysis.
  2. Characterize the intestinal microbiota through quantitative PCR and high throughput sequencing analysis of stool specimens in participants.

Aim 2. Compare sequencing results and metagenomic analysis for study groups with particular attention to bacterial composition and metabolic capacity associated with energy harvest, lipid and carbohydrate transport, enhancement of epithelial barrier integrity and systemic inflammation.

02

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • Polycystic Ovary Syndrome
  • Intestinal Microbiota
03

In context

Polycystic Ovary Syndrome

944 studies on the registry are indexed under Polycystic Ovary Syndrome; 174 are open to participants now.

This study's enrollment of 80 is below the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 242 studies on the registry; 144 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Polycystic Ovary Syndrome patients and age, BMI-matched women.

Eligibility criteria

Inclusion Criteria:

  1. Premenopausal between 18-40 years of age.
  2. Exclusion of other etiologies for infertility.

Exclusion Criteria:

  1. During the pregnancy and lactation period.
  2. Use of antibiotics within 3 months.
  3. Regular use of proton pump inhibitors, laxatives or pro-prebiotics.
  4. Previous history of gastrointestinal surgery or disease (such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease or other gastrointestinal disorder).
  5. Major changes in eating habits within the past 3 months.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Polycystic Ovary Syndrome

    Premenopausal women between 18-40 years of age. Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3): 1. chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days); 2. total or free T levels above the reference interval and/or excessive facial hair, acne; 3. transvaginal ultrasound with polycystic ovaries. Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency).

    Other: Blood Draw · Other: Stool collection

  • Control

    Women matched for age and BMI.

    Other: Blood Draw · Other: Stool collection

Interventions

  • OtherBlood Draw

    Blood sample will be drawn from participants at study entry.

  • OtherStool collection

    Stool will be collected from participants at study entry.

06

What researchers measure

Primary outcomes

  1. Intestinal microbiota of stool samples of PCOS and age, BMI-matched control will be identified by quantitative analysis.

    Time frame: an average of 1 month

Secondary outcomes

  1. Correlation of intestinal microbiota composition with biological parameters of PCOS patients will be assessed.

    Time frame: an average of 1 month

07

Study locations

1 site
  • Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02937090
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Responsible party
Dalong Zhu (Chief Physician, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Oct 18, 2016
Start date
May 2016
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Nov 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion